Egetis Therapeutics AB (publ) reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was SEK 22.6 million compared to SEK 38.2 million a year ago. Revenue was SEK 22.6 million compared to SEK 38.5 million a year ago.

Net loss was SEK 193.8 million compared to SEK 104.5 million a year ago. Basic loss per share from continuing operations was SEK 1 compared to SEK 0.6 a year ago. Diluted loss per share from continuing operations was SEK 1 compared to SEK 0.6 a year ago.